<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035891</url>
  </required_header>
  <id_info>
    <org_study_id>CQMU-2013-QLi</org_study_id>
    <nct_id>NCT02035891</nct_id>
  </id_info>
  <brief_title>Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria</brief_title>
  <official_title>Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The primary objective of this study was： in patients with type 2 diabetes and
           microalbuminuria who have been receiving stable treatment of angiotensin-converting
           enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) for at least 3 months,
           whether low-dose colchicine slows the progression of microvascular complications.

        2. The secondary objective of this study was： (1) whether low-dose colchicine could reduce
           Urinary Albumin To Creatinine Ratio (UACR), or improve eGFR in patients with type 2
           diabetes and microalbuminuria; (2) whether low-dose colchicine decreases carotid
           intima-media thickness(IMT) in patients with type 2 diabetes and microalbuminuria; (3)
           whether low-dose colchicine reduces the risk of cardiovascular events or mortality in
           patients with type 2 diabetes and microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND—Previous study reported that colchicine 0.5 mg/day, in addition to statins and
      other standard secondary prevention therapies, was effective for the prevention of
      cardiovascular events in patients with stable coronary disease. An experiment conducted by Li
      et al. showed that twenty-four-hour urinary albumin excretion was reduced after 6 months
      colchicine treatment in rats with diabetic nephropathy.As both micro and macrovascular
      complications of diabetes are closely associated with inflammation,with the anti-inflammation
      property,colchicine might reduce risk for micro and macrovascular complications of diabetes.

      STUDY DESIGN—Patients with type 2 diabetes and microalbuminuria(30mg/g Cr≤UACR≤300mg/g Cr)
      who have received stable dosage of ACEI/ARB for at least 3 months will be randomized to
      receive colchicine 0.5 mg/day or placebo.

      This trial includes four phases:

        -  Phases 1: A prospective, randomized，double-blind, control study, aims at evaluating
           microvascular events from date of randomization until the third year. Other parameters
           included evaluating changes of UACR, eGFR, CIMT from baseline to the follow-up.

        -  Phases 2: A prospective observational study, aims at evaluating macrovascular and
           microvascular events from date of randomization until the 6th year.

      SAFETY AND DATA MANAGEMENT-Independent Safety and Data Monitoring Committee has been set up
      to monitor the safety and tolerability of the subjects; this committee will analyze data
      independent of investigators at the end of any one phase.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of overt nephropathy</measure>
    <time_frame>3 years</time_frame>
    <description>overt nephropathy is defined as any one of the events described below: （1） UACR greater than 300 mg/g Cr; (2) 24 h urinary albumin greater than 300 mg; (3)doubling of the serum creatinine level to at least 200 μmol per liter; (4)the need for renal-replacement therapy;(5) death due to renal disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving at least a 15% reduction in UACR</measure>
    <time_frame>3 years</time_frame>
    <description>Renal outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>3 years</time_frame>
    <description>Renal outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who have new or worsening diabetic neuropathy</measure>
    <time_frame>3 years</time_frame>
    <description>diabetic neuropathy was assessed based on biothesiometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who have new or worsening diabetic retinopathy</measure>
    <time_frame>3 years</time_frame>
    <description>Diabetic retinopathy was diagnosed according to the six-level grading scale of the European Community- funded Concerted Action Programme into the Epidemiology and Prevention of Diabetes (EURODIAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in CIMT from baseline to the 3rd year</measure>
    <time_frame>18 months and 3 year</time_frame>
    <description>cardiovascular outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients who have new cardiovascular events</measure>
    <time_frame>6 years</time_frame>
    <description>cardiovascular events include death from cardiovascular causes, nonfatal stroke, nonfatal myocardial infarction, coronary-artery bypass grafting, percutaneous coronary intervention or revascularization for peripheral atherosclerotic arterial disease, and amputation because of ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of UACR</measure>
    <time_frame>6 years</time_frame>
    <description>evaluated at 6, 12, 18, 24, 36, 48, 60, 72 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of eGFR</measure>
    <time_frame>6 years</time_frame>
    <description>evaluated at 6, 12, 18, 24, 36, 48, 60, 72 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>6 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5mg/d colchicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>appearance is same as colchicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine 0.5mg/d</intervention_name>
    <description>on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.</description>
    <arm_group_label>colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 0.5mg/d</intervention_name>
    <description>on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Well informed of the procedures of this trial and informed consent is obtained

          -  Voluntarily accept standardized treatment

          -  30-70 years old, gender is not limited

          -  Diagnosed as type 2 diabetes and have received standardized hypoglycemic therapy

          -  Have been receiving stable doses of ACEI or ARBs for at least 3 months

          -  Two of three examinations of UACR at random urine are 30-300 mg/g Cr (infection or
             other factors were ruled out) in 3 months

          -  Well compliance

          -  Capable of self blood Glucose monitoring

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Type 1 diabetes

          -  Poor blood glucose control（HbA1c&gt;11%）

          -  A history of malignant tumor

          -  Abnormal liver or renal function (defined as alanine aminotransferase(ALT)&gt;2.5 times
             higher than normal range,or eGFR&lt;30 mL/min per 1•73 m²)

          -  Poor blood pressure control [systolic blood pressure(SBP)&gt;180mmHg,or diastolic blood
             pressure(DBP)&gt;110mmHg]

          -  With severe heart disease,cardiac function worse than grade II,anemia(Hb&lt;9.0g/d1)

          -  Continuous use of colchicine or non-steroidal anti-inflammatory drugs (except aspirin)
             more than one week in recent 3 months

          -  History of gout

          -  Blood routine test indicates that the white blood cell count(WBC) &lt;3*109/l

          -  Body Mass Index(BMI)&lt;18.5 or ≥35kg/m2

          -  Drug or alcohol abuse

          -  Accompanying mental disorder who can't collaborate

          -  Abnormal digestion and absorption function

          -  Other endocrine diseases

          -  Other chronic diseases needed long-term glucocorticoid treatment

          -  With severe infection, immune dysfunction

          -  A history of colchicine allergies or allergic constitution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19.</citation>
    <PMID>23265346</PMID>
  </reference>
  <reference>
    <citation>Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007 Mar 15;99(6):805-7. Epub 2007 Jan 16.</citation>
    <PMID>17350370</PMID>
  </reference>
  <reference>
    <citation>Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011 Jun;7(6):327-40. doi: 10.1038/nrneph.2011.51. Epub 2011 May 3. Review.</citation>
    <PMID>21537349</PMID>
  </reference>
  <reference>
    <citation>Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007 Jul 14;370(9582):153-160. doi: 10.1016/S0140-6736(07)61088-5.</citation>
    <PMID>17630038</PMID>
  </reference>
  <reference>
    <citation>de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.</citation>
    <PMID>21055801</PMID>
  </reference>
  <reference>
    <citation>ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.</citation>
    <PMID>18539916</PMID>
  </reference>
  <reference>
    <citation>Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999 Feb 20;353(9153):617-22.</citation>
    <PMID>10030326</PMID>
  </reference>
  <reference>
    <citation>ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.</citation>
    <PMID>22686416</PMID>
  </reference>
  <reference>
    <citation>Li JJ, Lee SH, Kim DK, Jin R, Jung DS, Kwak SJ, Kim SH, Han SH, Lee JE, Moon SJ, Ryu DR, Yoo TH, Han DS, Kang SW. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy. Am J Physiol Renal Physiol. 2009 Jul;297(1):F200-9. doi: 10.1152/ajprenal.90649.2008. Epub 2009 Apr 15.</citation>
    <PMID>19369290</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 4, 2014</study_first_submitted>
  <study_first_submitted_qc>January 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>director of the Endocrinology Department</investigator_title>
  </responsible_party>
  <keyword>colchicine</keyword>
  <keyword>urinary albumin-to-creatinine ratio</keyword>
  <keyword>carotid Intima-Media Thickness</keyword>
  <keyword>overt nephropathy</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

